title: [Observational study on urinary status following HoLEP].
abstract: We assessed the safety, and postoperative urinary status of holmium laser enucleation of the prostate (HoLEP) for the treatment of benign prostatic hyperplasia (BPH). Of the initial 117 patients who underwent HoLEP from November 2004 to March 2011, 49 were followed up for two yearsor longer. These 49 patients were evaluated once preoperatively, and at the 3rd, 6th, 12th, 24th, 48th, and 60th month postoperatively using International Prostate Symptom Scores (I-PSS) total and sub-score, quality of life score (QOL), maximum flow rate (Qmax), and post-voiding residual urine volume (PVR). The median estimated transition zone and enucleated volume were 45. 1 and 47. 9 g, respectively. Evaluation scores showed significant improvementsthroughout the follow-up. I-PSS total scoresimproved from 21 points(before surgery) to 6 points(12 monthsafter surgery), QOL scoresimproved from 5 pointsto 2 points, Qmax improved from 6.8 ml/s to 17.4 ml/s, and PVR improved from 101 ml to 26 ml, respectively. Transient urinary incontinence was noted in 14 patients (28.5%). One case showed a Clavien grade 3 complication of postoperative bleeding. No blood transfusion or re-surgery for BPH was required. In conclusion, HoLEP proved to be a safe and effective therapy, with potential to become a new gold standard for treating BPH.
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Yuka
authors.initials: Y
authors.lastname: Kono
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Keiyu
authors.initials: K
authors.lastname: Matsumoto
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Norihiko
authors.initials: N
authors.lastname: Masuda
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Shiraishi
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Negoro
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Noriaki
authors.initials: N
authors.lastname: Utsunomiya
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tsunemori
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Okubo
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Takuya
authors.initials: T
authors.lastname: Okada
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Takehiko
authors.initials: T
authors.lastname: Segawa
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Koei
authors.initials: K
authors.lastname: Muguruma
authors.affiliation: The Department of Urology, Kobe City Medical Center General Hospital.
authors.forename: Mutsushi
authors.initials: M
authors.lastname: Kawakita
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005500:Follow-Up Studies; D006801:Humans; D053844:Lasers, Solid-State / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D011468:Prostatectomy / Q000379:methods*; D011470:Prostatic Hyperplasia / Q000601:surgery; D016896:Treatment Outcome; D014554:Urination / Q000502:physiology*